Literature DB >> 10441163

Regression and spreading of self-recognition during the development of autoimmune demyelinating disease.

V K Tuohy1, M Yu, L Yin, J A Kawczak, P R Kinkel.   

Abstract

The autoimmune T cell repertoire in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) is characterized by CD4(+)T cells of the Th1 phenotype that recognize peptide determinants of central nervous system (CNS) myelin proteins in an MHC class II-restricted manner. Our recent studies and those performed by others have shown that progression to chronicity in EAE and MS is accompanied by a broadening of the T cell repertoire with time. This acquired neo-autoreactivity is commonly referred to as epitope spreading and is presumably the result of endogenous priming to new self-determinants during the CNS inflammation that accompanies disease onset and relapse. In the present study we extend our earlier observations by showing that disease progression in both EAE and MS is accompanied by two concurrent events, viz. (1) the spontaneous regression of the primary established autoimmune repertoire associated with disease onset, and (2) the emergence of the epitope spreading cascade associated with disease progression. Our data show that disease initiation and disease progression in both EAE and MS are typically associated with distinctly different autoimmune T cell repertoires. Our data support the view that the natural development of self-recognition during autoimmune disease may best be understood when considered in the temporal context of an 'epitope du jour' and 'moving target' perspective. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441163     DOI: 10.1006/jaut.1999.0293

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Authors:  Stefanie Kuerten; Dilyana A Kostova-Bales; Lukas P Frenzel; Justine T Tigno; Magdalena Tary-Lehmann; Doychin N Angelov; Paul V Lehmann
Journal:  J Neuroimmunol       Date:  2007-07-25       Impact factor: 3.478

2.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

3.  Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.

Authors:  Andreas Lutterotti; Sara Yousef; Andreas Sputtek; Klarissa H Stürner; Jan-Patrick Stellmann; Petra Breiden; Stefanie Reinhardt; Christian Schulze; Maxim Bester; Christoph Heesen; Sven Schippling; Stephen D Miller; Mireia Sospedra; Roland Martin
Journal:  Sci Transl Med       Date:  2013-06-05       Impact factor: 17.956

4.  Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  J Neuroimmunol       Date:  2013-08-01       Impact factor: 3.478

Review 5.  Restoring immune tolerance in neuromyelitis optica: Part I.

Authors:  Larry Steinman; Amit Bar-Or; Jacinta M Behne; Daniel Benitez-Ribas; Peter S Chin; Michael Clare-Salzler; Donald Healey; James I Kim; David M Kranz; Andreas Lutterotti; Roland Martin; Sven Schippling; Pablo Villoslada; Cheng-Hong Wei; Howard L Weiner; Scott S Zamvil; Michael R Yeaman; Terry J Smith
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-07

Review 6.  The major histocompatibility complex influences the ethiopathogenesis of MS-like disease in primates at multiple levels.

Authors:  B A 't Hart; H P Brok; S Amor; R E Bontrop
Journal:  Hum Immunol       Date:  2001-12       Impact factor: 2.850

Review 7.  Antigen-Specific Immune Tolerance in Multiple Sclerosis-Promising Approaches and How to Bring Them to Patients.

Authors:  Andreas Lutterotti; Helen Hayward-Koennecke; Mireia Sospedra; Roland Martin
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.